At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 10, 2026 at 08:05 ET
PDS Biotechnology announced that NantWorks exercised warrants for 17,699,115 shares at $0.22 per share, generating approximately $3.9 million in gross proceeds. The warrants were issued in connection with a September 2026 private placement that raised $11.3 million. Proceeds will fund advancement of PDS0301 toward a Phase 3 trial and partnership strategy for PDS0101.
- NantWorks exercised warrants to purchase 17,699,115 shares at $0.22 per share
- Gross proceeds to PDS Biotechnology were approximately $3.9 million
- Warrants were issued in connection with a September 14, 2026 private placement that raised $11.3 million
- Proceeds will support advancement of PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and partnership strategy for PDS0101
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access